AusBiotech 2017
Australia's Life Sciences Conference

Wednesday 25 October			
7:00am	**Conference Registration opens**		
9:00am	**BioIndustry Exhibition Hall opens**		
9:00am – 9:20am Hall A	**Official Opening & Welcome to AusBiotech 2017** **The Hon. Jay Weatherill MP**, The Premier of South Australia **Chair: Glenn Cross**, CEO, AusBiotech		
9:20am – 9:50am Hall A	**Keynote 1: Forming innovative partnerships to treat human diseases** **Barbara Sosnowski**, Vice President of External Science & Innovation (ES&I), Pfizer, United States		
9:50am – 10:30am Hall A	**Keynote 2: Building a global biotech from Australia** **Dr Silviu Itescu,** Chief Executive Officer and Managing Director, Mesoblast Limited		
10:30am – 11:00am	**Morning Tea & Networking with Exhibitors**		
11:00am – 12:30pm	**Concurrent Stream 1** Hall A	**Concurrent Stream 2** Room E1	**Regenerative Medicine 1** Room E2
	Medical Countermeasures *In a rapidly changing global environment, protection of Australian military and civilian personnel requires the development of medical countermeasures (MCM) which will identify and treat Chemical, Biological and Radiological (CBR) threats, emerging infectious*	**Australian innovation policy in Life Sciences** **Chair: Dr Hank Sciberras,** Partner, Global Investment and Innovation Incentives (G*i*^{3}), Co. Director, Deloitte Tax Services	**A strategic view of the regenerative medicine landscape: with the first cellular therapy products being approved, what is still needed to make them readily available to patients**

	diseases and pandemics. This session will present some of the new collaborative initiatives to improve MCM product development outcomes. **Chair: Dr Felicia Pradera**, Program Leader, Medical Countermeasures, DMTC Ltd **Dr Leigh Farrell**, VP Corporate Strategy & Business Development, Certara **Mark Hodge**, CEO, DMT **Sacha Dopheide**, General Manager, nplex, Planet Innovation **Dr Glenn Marsh**, Senior Research Scientist, CSIRO	**Glenn Cross**, CEO, AusBiotech **Sue MacLeman**, CEO, MTPConnect **Adrian White**, Manager Health Technologies Policy, Industry Growth Division, Department of Industry, Innovation and Science **Paul Cross**, Director, Biotech Dispatch Deloitte.	**Introduction: Silvio Tiziani**, CEO, Australia Regenerative Medicine Institute *AusBiotech and Regenerative Medicine initiatives* **Chair: Dr Silviu Itescu**, Chief Executive Officer and Managing Director, Mesoblast Limited **Dr Dominic Wall**, Chief Scientific Officer, Cell Therapies Pty Ltd *Manufacturing and supply: scaling cellular therapies up and out for commercial supply* **Dr Tony Manderson**, Principal Adviser, Biological Science, Scientific Evaluation Branch, TGA *Regulation of clinical trials and commercial products* **Dr Michael May**, CEO, Centre for Commercialisation of Regenerative Medicine (CCRM) *Reimbursement of cellular therapies: challenges, solutions and implications for target selection* **Lawrence Gozlan**, CEO, Scientia Capital *What are investors looking for in regenerative medicine now?*

12:30pm – 1:30pm Hall A	**AusBiotech Annual General Meeting (AusBiotech members only) and Board Meeting**		
12:30pm – 1:30pm	**Lunch & Networking with Exhibitors**		
1:30pm – 3:00pm	**Concurrent Stream 3** Hall A	**Concurrent Stream 4** Room E1	**Regenerative Medicine 2** Room E2
	Complementary medicine/health **Chair: Dr. Graeme Smith,** New Product Opportunity Manager – Global, Swisse Wellness **Gabriel Liberatore**, General Manager, Research & Development, Swisse Wellness *overview of the complementary medicines industry/sector* **Dr Allison Jones**, Director, Listing Compliance, Complementary and OTC Medicines Branch, Department of Health *Complementary medicine current legislation and potential reform*	**Ownership and transfer of rights: an intellectual property case study** **Chair: Dr Lisa A. Haile**, Partner and Co-Chair, Global Life Sciences Sector, DLA Piper, United States **Sakura Holloway**, Investment Analyst, OneVentures **Stephen Rodda**, Chief Executive Officer, UniSA Ventures Pty Ltd, University of South Australia **Jenny Petering**, Of Counsel, FB Rice **Geraldine Farrell**, Nexvet Integration Project Manager (formerly General Counsel & VP Operations), Nexvet Biopharma plc, part of Zoetis	**International regenerative medicine opportunities and perspectives** **Chair: Silvio Tiziani**, CEO, Australia Regenerative Medicine Institute **Korean spotlight** **Chair: Dr Bryan Choi,** Professor, Department of Biomedical Sciences, Medical College of Inha Univ, Korea **Dr Sora Park**, Dean of Medical College of Inha Univ, Korea *Korea's regenerative medicine market and its development strategy Introduction of CARM(Council for Advanced Regenerative Medicine)*

	Prof Lynne Cobiac, Deputy Director & Science Director, Health and Biosecurity, CSIRO *Precision health and wellness* Swisse	DLA PIPER	**Dr Yunmi Kim**, Manager, Business Development, Medipost *CARTISTEM: Commercial stage Allogeneic Stem Cell Product for Osteoarthritis* **Dr Benjamin Chong**, Team Manager, Cellular Therapeutics, Daewoong Pharmaceutical Co Ltd *ES-derived MSC: a breakthrough in current drawbacks of adult stem cells* **Dr Sun U. Song**, CEO, SCM Life Science *Clonal Mesenchymal Stem Cells for the Treatment of Immune Diseases* **Japanese spotlight** **Dr Akihiko Iwai**, Vice Deputy Chairman of Forum for Innovative Regenerative Medicine (FIRM) and Divisional Senior Vice President of Candidate Discovery Science Labs, Drug Discovery Research, Astellas Pharma Inc. *Government support, regulatory environment and industry profiles from FIRM point of view* **Colin Lee Novick**, Managing Director, CJ PARTNERS Inc *Recent commercial activities and opportunities between Australia and Japan*

			Israeli spotlight **Shir Mnuchin**, VP, Partnerships Connecting Industry, Academia and Government, Bioforum Ltd.
3:00pm – 3:30pm	**Afternoon Tea & Networking with Exhibitors**		

3:30pm – 3:45pm Hall A	**Announcement and presentation of the AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards 2017** **Kathy Connell,** Senior Director New Ventures, ANZ, Johnson & Johnson Innovation **Glenn Cross,** CEO, AusBiotech Johnson & Johnson INNOVATION	**Regenerative Medicine 3 (**Room E2) **What technologies are hot in regenerative medicine now and in the future?** **Chair: Dr Dianne Jackson Matthews,** ERA Consulting **Prof Melissa Little**, Director, Stem Cells Australia *Transitioning to the Future: Australia's stem cell future* **Prof Simon Barry**, Senior Research Fellow, Uni SA, Founder, Carina Biotech *Immunotherapy: what next after CD19 CAR-T?* **Dr Geoff Symonds,** Head of Scientific Affairs and Collaborations, Calimmune *Gene therapy and gene editing: technologies and tactics to move out of rare diseases* **Dr Kilian Kelly,** Vice President Product Development, Cynata Therapeutics *Next generation stem cells: iPSC potential*
3:45pm – 5:00pm Hall A	**Plenary 1: Key issues facing big pharma globally** **Chair: Lorraine Chiroiu**, Deputy Chief Executive Officer, AusBiotech Ltd **Panel:** **Benjamin Thorner**, Senior Vice President and Head of Business Development & Licensing, Merck Research Laboratories **Dr Kevin Lynch**, Vice President Search & Evaluation, AbbVie, United States **Dr Anand Gautam**, Senior Director, Head of External Science & Innovation, Australia, New Zealand and Southeast Asia, Pfizer Australia **Jessica Droge**, Executive Director, Business Development, Amgen Inc, United States **Kathy Connell,** Senior Director New Ventures, ANZ, Johnson & Johnson Innovation **Dr Marie Lindner,** Global Program Head of the Strategic Partnerships team, Novartis	

5:30pm – 7:00pm	**AusBiotech 2017 Welcome Reception** **BioIndustry Exhibiton Hall**

Thursday 26 October	
7:00am – 8:30am	**TechInSA Reception –** see satellite events on the event website John Halbert Room, Adelaide Oval – *within walking distance to the Adelaide Convention Centre*
9:00am – 5:00pm	**Bionomics-Merck Annual Symposium –** *separate program on the event website* Riverbank Rooms 3 and 4, Adelaide Convention Centre
9:00am – 10:40am Hall A	**Plenary Session 2: Millis Oration** **Chair: Dr Andrea Huggins**, Senior Director & Head, Global Licensing, CSL **Dr C. Glenn Begley**, Chief Executive Officer, Biocurate Pty Ltd **Plenary Session 3: Drug Development in fast forward: Lean, value-focused drug development strategies of the future** **Craig Rayner**, President, d3 Medicine a Certara company **Chair: Glenn Cross**, CEO, AusBiotech **Announcement of the MTPConnect Grants | Department of Innovation, Industry & Science Minister** **Release of report – Australian life sciences sector – a snapshot 2017 | Glenn Cross,** CEO, AusBiotech

10.40am – 11.10am	**Morning Tea and Networking with Exhibitors**		
	Concurrent Stream 5 Hall A	**Concurrent Stream 6** Room E1	**Clinical Trials 1** Room E2
11:10am – 12:40pm	**Pitfalls and tips for early stage biopharmaceutical manufacturing** *As biotech companies navigate the stages of drug development there are many potential pitfalls that can derail progress towards commercialisation. An important part of this journey is identifying, planning and executing the right manufacturing strategy. The challenges that can arise during early stage biomanufacturing and tips to manage them will be examined in this presentation with perspectives from the drug developer, the venture capital manager and the manufacturer.* **Evan Shave**, Associate Director, Global Tech Transfer, Process Engineering and Validation, Patheon **Mike Gerometta**, Head of CMC, Opthea **Sarah Meibusch**, Investment Manager, OneVentures.	**Enhancing commercialisation success of infectious disease products – Australian and international perspectives** **Chair: Jennifer Herz**, Managing Director, Biointelect Pty Ltd **Prof Jodie McVernon**, Professor and Director of Doherty Epidemiology, Doherty Institute *Opportunities for the Australian Partnership for Preparedness Research on Infectious Diseases Emergencies (APPRISE) Centre for Research Excellence* **Prof Seshadri Vasan**, Senior Business Development Manager, Public Health England, UK and University of York *Initiatives and funding models – the European perspective* **Dr Leigh Farrell**, VP Corporate Strategy & Business Development, Certara	**Bench to Biotech - how to ensure your best chance of technical and commercial success** *Overview of what investors are looking for; optimising strategic, commercial and technical planning for success; and using big data to inform clinical development decision-making* **Chair: Lorraine Chiroiu**, Deputy CEO, AusBiotech **Jérôme Armellini**, Head of Asia Therapeutic Strategy, Therapeutic Science & Strategy Asia Pacific, QuintilesIMS **Dr Robert Gallagher**, Senior Principal and Head of Strategic Clinical Development Consulting, Asia-Pacific, QuintilesIMS **Chris Smith**, Investment Manager, Brandon Capital

	Patheon	*Initiatives and funding models – the North American perspective* **David Abbott**, Director Emerging Issues, NHMRC *Initiatives and funding models – the Australian / NHMRC perspective*	QuintilesIMS™
12:40pm – 1:40pm	**Lunch and Networking with Exhibitors**		
	Concurrent Stream 7 Hall A	**Concurrent Stream 8** Room E1	**Clinical Trials 2** Room E2
1:40pm – 3:10pm	**Chair: David Fuller**, Senior Vice President, Regional Head AsiaPacific Hematology/Oncology**,** INC Research/inVentiv Health **Dr. Skye Hodson,** Senior Strategy Consultant**,** INC Research/inVentiv Health *The Benefits of integrating the clinical and commercial organisations early-on in product development for successful outcomes in partnering and commercialization* **Dr Caroline Popper**, Co-Founder and President, Popper and Co., United States	**Cyber Risks** *The Internet of healthcare is fast arriving. Medical devices are now capable of connecting to networks and the internet to bring significant benefits to patients and healthcare staff alike. This connectivity also comes with risk, notably the risk of the device being hacked by someone with malicious or criminal intent. This session review some of the recent major hacks in medical products and identify what went wrong, and review insurance options to protect in the event cyber attack.* **Travis McIntosh**, Life Science Specialist Asia Pacific, Chubb Insurance **Damien Miller**, Information Security Engineer, Google	**Australian clinical trials – in an international context** **Chair: Kylie Sproston**, CEO, Bellberry *Localising international clinical trials - Typical issues when introducing an international clinical trial protocol into the Australian health environment: eg Medicare/payer considerations, comparator considerations, geography and identification, vulnerable groups, etc.* **Melanie Gentgall**, CEO, Praxis *Australian regulations - Similarities, differences and key points to remember about Australia vs other jurisdictions: eg FDA vs TGA, HREC vs IRB, SAE reporting*

	"Smart diagnostics": the key to realising the potential of precision medicine *(discussion of current and future trends in advanced diagnostics and pharma's response)* inc Research inVentiv Health	**Andrew Taylor**, Cyber Product Manager Asia Pacific, Chubb Insurance CHUBB	*changes, local sponsor requirements, GCP.* **Prof Annette Braunack-Mayer**, Adelaide University & HREC Chair (Bellberry HREC F and SA Health HREC) *Hot topics in ethical research - Hear from an HREC Chair about the ethical aspects of current clinical trial innovations, and how to manage them: such changes in consent processes, supporting digital tools, social media advertising/recruitment.* **Sophie Mepham**, National Research Manager, Genesis CancerCare *The view from the frontline - Hear the Site perspective and understand what they would like Sponsor organisations to know pre-feasibility. Understand the nuances of the Australian health sector, and how that may impact on a trial protocol and research program.*
3:10pm – 3:40pm	**Afternoon Tea & Networking with Exhibitors**		

3:40pm – 5:10pm	**Plenary Session 4 (Hall A): Performance of the Australian biotech sector - with a focus on drug development companies** **Peter Molloy**, Chief Executive Officer, Race Oncology **Plenary Session 6: Global Investment update** Chair: **Lawrence Gozlan**, CEO, Scientia Capital **James Clark**, Head Of Tech And Lifesciences, London Stock Exchange **Anne-Marie Birkill**, Partner, OneVentures	**Plenary Session 5 (Room E1): The Medicines Discovery Catapult : A national UK centre supporting biotech into a new era** **Chair: Judy Halliday**, Director Industry Development, TechInSA **Chris Molloy**, CEO, Medicines Discovery Catapult	**Clinical Trials 3 (Room E2)** **The Connected Journey of Data Driven Drug Development** **Chair: Michelle Major**, Senior Director, Project Leadership, Phase II/III, PAREXEL International *Planning for success-designing and conducting optimal global drug development programs* **Dr John Lambert,** Vice President and Global Head, Early Phase Medical Sciences, PAREXEL International Translational Sciences and Adaptive Designs to Optimize Early Clinical Development *Translational Sciences and Adaptive Designs to Optimize Early Clinical Development* **Natasha Steyn**, Director, Clinical Operations, PAREXEL International *Optimizing Late Phase Trials with Risk Based Monitoring*

7:00pm – 11:00pm	**Conference Dinner** **Panorama Room, Adelaide Convention Centre**	
Friday 27 October		
9.00am – 11.00am	**BioIndustry Exhibition Hall Trade Morning**	
9:40am – 10:20am Hall A	**Plenary Session 7: Update on the Innovation, Science and Research System Review/2030 Strategic Plan** **Chair: Glenn Cross**, CEO, AusBiotech **Charlie Day**, Chief Executive Officer, Office of Innovation and Science Australia	
10:20am – 11:00am	**Morning Tea and Networking with BioIndustry Exhibitors**	
11:00am – 11:30am Hall A	**Plenary Session 8: Inventing supply chains for 21st century cures – implications for product development** **Chair: Joe Thorp**, CEO, TechInSA **Dr Tim Oldham,** Chief Executive Officer, Cell Therapies	
	Concurrent Stream 9 Hall A	**Concurrent Stream 10** Room E1

11:30am – 1:00pm	**Getting into preclinical testing: Australia's development capabilities** *We now have money flowing into biotech/pharma and through the R&D Tax Incentive, angel investor tax breaks, the BTF. We have the acknowledgment that translation is key. So once you have the IP and an indication of your development path, where do you go to get advice and where are the capabilities for development and testing for your preclinical proof-of-concept and preclinical studies. What capabilities are available in Australia and what is needed?* **Chair: Julie Phillips**, Chief Executive Officer, BioDiem Ltd **Richard Buchta**, Formulytica Pty Ltd **Dr Ralf Brandt**, President Discovery and Early Development, Vivopharm **Dr Joe Desneves**, Senior Business Development Executive, IDT **Dr John Kurek**, Investment Manager, UNISEED	**Innovation For Commercialisation** *Successful commercialisation of a new product challenges the developer's depth and accuracy of their understanding about the intended customer and market. This knowledge is essential in moulding the product features and characteristics to best penetrate and compete in a global market before competitively communicating the product value to customers and securing successful sales. While the products developed in the biotech industry emanate from complex and sophisticated science and compete in an even more complex and multi-layered market structure, the principles behind successful commercialisation are just as valid. This panel will discuss the strategic, legal, investor and customer perspectives facing biotech product commercialisation in Australia today.* **Chair: Dr Elane Zelcer,** Commercialisation Adviser, Accelerating Commercialisation, Innovation Programmes **Lusia Guthrie**, Chairman, Clever Culture Systems **Rob McInnes,** Partner, DibbsBarker **Dr Ingmar Wahlqvist,** Investment Manager, Brandon Capital Partners **Michelle Burke,** Principal and Director, Indigo Advisory
1:00pm – 2:30pm	**AusBiotech 2017 Closing celebration* and hand over to AusBiotech 2018** **Glenn Cross, CEO AusBiotech** **Lea Diffey, Executive Director, Science Development, Department of Science, Information Technology and Innovation, Queensland Government** **Terence Walsh, Regional Exec, MasterControl** **BioIndustry Exhibition Hall**	MasterControl

	Food and beverages will be served during the closing celebration
2:00pm – 5:30pm	**One Ventures/TechinSA, Making a project investable (invitation only)** Skyway Rooms 1-3